Seoul, January 11, 2026 – Coreline Soft announced that its AI-based lung cancer screening software,
AVIEW LCS, has been designated under Korea’s Conditional New Health Technology Assessment pathway by the Ministry of Health and Welfare.
The Conditional pathway allows technologies with established safety profiles to enter clinical practice on a temporary, non-reimbursed basis while additional clinical evidence is generated. During the designated period, AVIEW LCS may be implemented across medical institutions in Korea, enabling structured data collection to support future full assessment and potential reimbursement discussions.
This designation establishes a formal regulatory pathway for AVIEW LCS within Korea’s healthcare system and reflects growing recognition of AI-based decision support in large-scale screening environments.
Alignment with Global Screening Expansion
The milestone coincides with accelerating policy discussions across Europe regarding the institutionalization of low-dose CT (LDCT) lung cancer screening.
Germany’s Federal Joint Committee (G-BA) has proposed nationwide implementation of LDCT-based lung cancer screening within statutory health insurance, while France is preparing a targeted national pilot program beginning in 2026. In this evolving landscape, AI technologies are increasingly considered important components in addressing interpretation workload, standardization, and longitudinal management in screening programs.
Coreline Soft’s solutions have been deployed in multiple European lung cancer screening initiatives, contributing operational and technical experience in structured screening environments.
A Step Toward Screening Infrastructure
“As lung cancer screening expands globally, the role of AI is evolving from research-stage tools to infrastructure-level support technologies,” said Jinkook Kim, CEO of Coreline Soft. “This designation enables us to generate further clinical evidence in Korea while building on our experience in European national screening projects.”
Coreline Soft will continue to collaborate with clinical and policy stakeholders to support sustainable, data-driven lung cancer screening systems.
List